Trial Profile
A Phase 1, Double Blind, Crossover, Placebo-Controlled, Dual-Injection, Safety and Pharmacokinetic Study of AI-700 in Patients With Diminished DLCO and Chronic Obstructive Pulmonary Disease (COPD) and/or Congestive Heart Failure (CHF)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Jun 2014
Price :
$35
*
At a glance
- Drugs Perflubutane (Primary)
- Indications Chronic obstructive pulmonary disease; Heart failure
- Focus Diagnostic use
- Sponsors Acusphere
- 05 Jun 2014 New trial record